1. Publication
- Title: Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial
- Acronym: DOTS
- Year & Journal: JAMA, published August 13, 2025 (2025;334(10):866-877)
- Citation: Turner NA, Hamasaki T, Doernberg SB, et al; Antibacterial Resistance Leadership Group (ARLG). JAMA. 2025;334(10):866-877. doi:10.1001/jama.2025.12543
2. Context & Rationale
Background: Complicated S. aureus bacteremia typically requires 4-8 weeks of parenteral therapy via a PICC line, carrying risks of catheter-associated infections, thrombosis, and other complications. Dalbavancin, a long-acting lipoglycopeptide, could complete treatment without durable IV access.
Research Question/Hypothesis: In patients with complicated S. aureus bacteremia who have cleared bacteremia after ≥72h of effective therapy, is two-dose dalbavancin (one week apart) as effective as standard therapy for completing treatment, per Desirability of Outcome Ranking (DOOR) at day 70?
3. Design & Methods
- Study Type: Phase 2b, multicenter, randomized, open-label, assessor-masked, active-controlled, superiority trial
- Setting & Centers: 23 centers, US (22) and Canada (1); April 2021–December 2023
- Population: Adults with complicated S. aureus bacteremia (including definite/possible right-sided endocarditis), treated ≥72h (max 10 days) with clearance of bacteremia prior to randomization
- Intervention: Two IV doses of dalbavancin, one week apart
- Comparator: Standard-of-care parenteral therapy (typically via PICC)
- Blinding: Open-label treatment, assessor-masked outcome evaluation
- Statistical Power & Follow-Up: Target enrollment 200. Primary: Desirability of Outcome Ranking (DOOR) at day 70.
4. Key Results
Outcome | Dalbavancin | Standard Therapy | Notes |
DOOR at day 70 (primary) | Favored dalbavancin 47.7% of comparisons | — | Not statistically superior (did not hit superiority threshold) |
Clinical efficacy | Matched standard therapy | — | Comparable clinical outcomes |
Safety/tolerability | Well tolerated | — | No major safety signal |
5. Internal Validity Assessment
Assessor-masked outcome evaluation despite open-label treatment delivery — a meaningful design strength for a superiority trial testing a device-free (no PICC) alternative. Overall: Moderate-to-strong — did not hit statistical superiority, but clinical efficacy matched standard care with a well-tolerated safety profile.
6. External Validity Assessment
Multicenter US/Canada population with complicated S. aureus bacteremia including endocarditis — directly relevant to the population for whom PICC-line-associated risks are most consequential.
7. Strengths & Limitations
Strengths: Assessor-masked outcomes; addresses genuine PICC-related complication burden; matched efficacy with a far simpler regimen (2 doses vs weeks of daily infusions).
Limitations: Did not meet statistical superiority; DOOR ranking did not incorporate quality-of-life factors like ability to discharge home without an IV catheter.
8. Interpretation & Practice Impact
Supports dalbavancin as a viable option for completing treatment of complicated S. aureus bacteremia, avoiding PICC-related risks and enabling earlier discharge — not proven statistically superior, but a genuine additional choice for patients with barriers to long-term IV access.
9. Controversies & Subsequent Evidence
Independent commentary (NEJM Journal Watch HIV/ID blog) offers "optimism around a negative trial," noting that despite missing statistical superiority, dalbavancin performs about as well as current standard care with far less infrastructure (no PICC, no daily infusions, no vancomycin levels) — economics may favor it once accounting for early-discharge cost savings, even without a DOOR-detected efficacy advantage. An accompanying commentary ("DOT-ting i's and crossing t's") similarly supports considering dalbavancin an option to complete therapy.
10. Summary & Executive Takeaway
Summary: DOTS randomized adults with complicated S. aureus bacteremia (cleared, ≥72h treated) across 23 US/Canada centers to two-dose dalbavancin or standard parenteral therapy. DOOR at day 70 favored dalbavancin in 47.7% of comparisons — not statistically superior — but clinical efficacy matched standard therapy with good tolerability.
Overall Takeaway: Dalbavancin did not prove statistically superior but performs comparably to standard therapy for completing treatment of complicated S. aureus bacteremia, offering a genuine, infrastructure-light alternative (2 doses vs weeks of PICC-based therapy) for patients with barriers to long-term IV access — an additional evidence-based choice rather than a new standard of care.
11. Bibliography
- Turner NA, Zaharoff S, King H, et al. DOTS study protocol. Trials. 2022;23(1).
- Zambrano S, Paras ML, Suzuki J, et al. Real-world dalbavancin use for serious gram-positive infections. Open Forum Infect Dis. 2024;11:ofae186.